Navigation Links
Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market
Date:5/26/2011

NEW YORK, May 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market

http://www.reportlinker.com/p0512133/Opioids-Market-to-2017---Steady-Uptake-of-Oxycontin-and-High-Incidence-Of-Diseases-Such-As-Cancer-And-Arthritis-to-Drive-the-Market.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market", which provides insights into global opioids market and market forecast until 2017. The report provides an in-depth analysis of the top seven therapeutic indications for which often opioids are prescribed which includes fibromyalgia, neuropathic pain, cancer pain, osteoarthritis pain, rheumatoid arthritis pain, low back pain and post operative pain. The report also examines the global opioids treatment usage patterns for the covered indication. In addition, the report also includes insights into the opioids R&D pipeline.

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis shows that the overall global opioids market for the seven indications fibromyalgia, neuropathic pain, cancer pain, osteoarthritis pain, rheumatoid arthritis pain, low back pain and post operative pain was valued at $11.2 billion in 2010. The market is expected to witness a CAGR of 2.8% for the forecast period. Patent expiries of leading opioids followed by generic erosions along with adverse effects associated with use of opioids are the main reasons for marginal growth in opioids market. However expected launch of new opioids is expected to push the market in future.

The US was the largest region for the opioids market in terms of revenue, accounting for 49% followed by top five countries in Europe and Japan which contributed 36% and 15% respectively.

The top pharmaceutical companies in opioids market are – Johnson & Johnson, Cephalon and several mid size players such as Purdue Pharma, King Pharmaceuticals, Orexo and Endo Pharmaceuticals. Large amount of fragmentation in the market provides significant scope for consolidation through mergers and acquisitions.

Scope

The scope of this report includes -

- Data and analysis on the global opioids market.

- Annualized market data for the opioids market from 2002 to 2010, with forecasts to 2017.

- Market data on the therapeutic landscape which covers fibromyalgia, neuropathic pain, cancer pain, osteoarthritis pain, rheumatoid arthritis pain, low back pain and post operative pain therapeutics including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.

- Key drivers and restraints that have had a significant impact on the market and on each indication.

- The competitive landscape of the global opioids market which includes companies such as Johnson & Johnson, Cephalon, Purdue Pharma, King Pharmaceuticals, Orexo and Endo Pharmaceuticals.

- Key M&A activities and Licensing Agreements that took place from 2005 to 2010 in the global opioids market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.

- Device a more tailored country strategy through the understanding of key drivers and barriers of the region's opioids market.

- Develop key strategic initiatives by understanding the key focus areas and top selling opioids molecules of leading companies.

- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 8

2 Opioids Market to 2017: Introduction 11

2.1 GBI Research Report Guidance 11

3 Opioids Market: Market Overview 13

3.1 Introduction 13

3.2 Opioids: A Classification 13

3.2.1 Branded Generics Play a Major Role 15

3.2.2 Novel Drug Delivery Techniques Push Opioid Usage 15

3.3 Adverse Effects Associated With Opioids Restrain Its Prescription 16

3.4 REMS 17

3.4.1 What are REMS? 17

3.4.2 Implications of REMS 18

3.4.3 REMS for Opioids 19

3.5 Revenue 20

3.6 Major Marketed Opioids 21

3.6.1 Oxycontin 21

3.6.2 Embeda 22

3.6.3 Exalgo 23

3.6.4 Onsolis 24

3.6.5 Avinza 25

3.6.6 Duragesic 26

3.6.7 Kadian 27

3.6.8 Opana ER 27

3.6.9 Vicodin CR 28

3.6.10 Dolophine 29

3.6.11 MS Contin 30

3.6.12 Oramorph 30

3.7 FDA Regulations Regarding Opioids 33

3.7.1 FDA Regulations on Opioid Combinations with Acetaminophen 33

3.7.2 Darvocet, Darvon (Propoxyphene) Withdrawn From the Market 33

3.8 Annual Cost of Therapy 33

3.9 Treatment Usage Patterns 34

3.9.1 Diseased Population 36

3.9.2 Treatment Seeking Population 37

3.9.3 Diagnosed Population 38

3.9.4 Prescription Population 39

3.10 Drivers and Restraints of the Opioids Market 40

3.10.1 Drivers 40

3.10.2 Restraints 41

4 Opioids Market: Therapeutic Landscape 42

4.1 Opioids Market for Fibromyalgia 42

4.1.1 Introduction 42

4.1.2 Revenue and Forecasts 42

4.1.3 Annual Cost of Therapy 44

4.1.4 Treatment Usage Patterns 45

4.1.5 Geographical Segmentation 50

4.2 Drivers and Restraints for the Opioids Market for Fibromyalgia 52

4.2.1 Drivers 52

4.2.2 Restraints 53

4.3 Opioids for Neuropathic Pain 54

4.3.1 Introduction 54

4.3.2 Revenue and Forecasts 54

4.3.3 Annual Cost of Therapy 55

4.3.4 Treatment Usage Patterns 56

4.3.5 Geographical Segmentation 62

4.4 Drivers and Restraints for the Opioids Market for Neuropathic Pain 64

4.4.1 Drivers 64

4.4.2 Restraints 64

4.5 Opioids Market for Cancer Pain 65

4.5.1 Introduction 65

4.5.2 Revenue and Forecasts 66

4.5.3 Annual Cost of Therapy 67

4.5.4 Treatment Usage Patterns 68

4.5.5 Geographical Segmentation 74

4.5.6 Drivers and Restraints for the Opioids Market for Cancer Pain 76

4.5.7 Drivers 76

4.5.8 Restraints 77

4.6 Opioids Market for Osteoarthritis Pain 77

4.6.1 Introduction 77

4.6.2 Revenue and Forecasts 78

4.6.3 Annual Cost of Therapy 79

4.6.4 Treatment Usage Patterns 80

4.6.5 Geographical Segmentation 85

4.6.6 Drivers and Restraints for the Opioids Market for Osteoarthritis Pain 87

4.6.7 Drivers 87

4.6.8 Restraints 88

4.7 Opioids Market for Rheumatoid Arthritis Pain 88

4.7.1 Introduction 88

4.7.2 Revenue and Forecasts 88

4.7.3 Annual Cost of Therapy 89

4.7.4 Treatment Usage Patterns 91

4.7.5 Geographical Segmentation 96

4.7.6 Drivers and Restraints for Opioids Market for Rheumatoid Arthritis Pain 98

4.7.7 Drivers 98

4.7.8 Restrains 98

4.8 Opioids Market for Low Back Pain 99

4.8.1 Introduction 99

4.8.2 Revenue and Forecasts 99

4.8.3 Annual Cost of Therapy 100

4.8.4 Treatment Usage Patterns 101

4.8.5 Geographical Segmentation 106

4.8.6 Drivers and Restraints for the Opioids Market for Low Back Pain 108

4.8.7 Drivers 108

4.8.8 Restraints 108

4.9 Opioids Market for Post-operative Pain 109

4.9.1 Introduction 109

4.9.2 Revenue and Forecasts 109

4.9.3 Annual Cost of Therapy 110

4.9.4 Treatment Usage Patterns 111

4.9.5 Geographical Segmentation 117

4.9.6 Drivers and Restraints for the Opioids Market for Post-operative Pain 119

4.9.7 Drivers 119

4.9.8 Restraints 119

4.10 Opioids Market for Other Indications 120

4.10.1 Introduction 120

4.10.2 Revenue 120

5 Opioids Market: Geographical Landscape 121

5.1 The US 123

5.1.1 Revenue and Forecasts 123

5.1.2 Annual Cost of Therapy 125

5.1.3 Treatment Usage Patterns 126

5.2 Top Five Countries in Europe 132

5.2.1 Revenue and Forecasts 132

5.2.2 Annual Cost of Therapy 133

5.2.3 Treatment Usage Patterns 134

5.3 Japan 139

5.3.1 Revenue and Forecasts 139

5.3.2 Annual Cost of Therapy 140

5.3.3 Treatment Usage Patterns 141

6 Opioids Market: Pipeline Analysis 146

6.1 Introduction 146

6.1.1 Research and Development Pipeline – Neuropathic Pain 148

6.1.2 Research and Development Pipeline – Cancer Pain 149

6.2 Profiles of Key Late-Stage Drugs in the Opioids Market 149

6.2.1 Fentanyl TAIFUN - AKELA Pharma Inc. 149

6.2.2 Fentanyl Sublingual Spray - INSYS Therapeutics, Inc. 150

6.2.3 Oxycodone hydrochloride - Mundipharma International Limited 150

6.2.4 CEP-33237 - Cephalon, Inc. 150

6.2.5 ELI-216 - Elite Pharmaceuticals, Inc. 150

7 Opioids Market: Competitive Landscape 152

7.1 Competitive Profiling 152

7.1.1 King Pharmaceuticals 152

7.1.2 Johnson & Johnson 153

7.1.3 Orexo AB 155

7.1.4 Endo Pharmaceuticals 155

7.1.5 Cephalon, Inc. 157

7.1.6 Purdue Pharma 158

7.1.7 Mundipharma 159

8 Opioids Market: Strategic Consolidations 160

8.1 Overview 160

8.1.1 M&A Deals by Indication 160

8.1.2 M&A Deals by Geography 161

8.1.3 M&A Deals by Value ($) 162

8.2 R&D Licensing Agreements 165

8.2.1 Deals by Indication 165

8.2.2 Deals by Geography 166

8.2.3 Deals by Phase 167

8.2.4 Deals by Value ($) 168

8.2.5 Deals by Type 169

8.3 Co-development Deals 170

9 Opioids Market: Appendix 172

9.1 Market Definitions 172

9.2 Abbreviations 172

9.3 Research Methodology 173

9.3.1 Coverage 173

9.3.2 Secondary Research 174

9.3.3 Primary Research 174

9.3.4 Expert Panel Validation 176

9.4 Contact Us 176

9.5 Disclaimer 176

9.6 Sources 176

1.1 List of Tables

Table 1: Opioids Market, Global, Revenue ($bn), 2002–2010 21

Table 2: Opioids Market, Global Revenue ($bn), 2010–2017 21

Table 3: Global Revenue of Top Selling Opioids ($'000), 2007–2009 32

Table 4: Major Marketed Opioid Drugs 32

Table 5: Opioids Market, Global, Annual Cost of Therapy ($), 2002–2010 34

Table 6: Opioids Market, Global, Annual Cost of Therapy ($), 2010–2017 34

Table 7: Opioids Market, Global Treatment Usage Patterns (million), 2002–2010 35

Table 8: Opioids Market, Global Treatment Usage Patterns (million), 2010–2017 35

Table 9: Opioids Market, Fibromyalgia Global Revenue ($m), 2002–2010 43

Table 10: Opioids Market, Fibromyalgia Global Revenue ($m), 2010–2017 43

Table 11: Opioids Market, Fibromyalgia Global Annual Cost of Therapy ($), 2002–2010 44

Table 12: Opioids Market, Fibromyalgia Global Annual Cost of Therapy ($), 2010–2017 44

Table 13: Opioids Market, Fibromyalgia Global Treatment Usage Patterns (million), 2002–2010 45

Table 14: Opioids Market, Fibromyalgia Global Treatment Usage Patterns (million), 2010–2017 46

Table 15: Opioids Market, Fibromyalgia Global Market Geographical Segmentation ($m), 2002–2010 51

Table 16: Opioids Market, Fibromyalgia Global Market Geographical Segmentation ($m), 2010–2017 51

Table 17: Opioids Market, Global, Neuropathic Pain Revenue ($m), 2002–2010 55

Table 18: Opioids Market, Global, Neuropathic Pain Revenue ($m), 2010–2017 55

Table 19: Opioids Market, Global, Neuropathic Pain Annual Cost of Therapy ($), 2002–2010 55

Table 20: Opioids Market, Global, Neuropathic Pain Annual Cost of Therapy ($), 2010–2017 56

Table 21: Opioids Market, Global, Neuropathic Pain Treatment Usage Patterns (million), 2002–2010 57

Table 22: Opioids Market, Global, Neuropathic Pain Treatment Usage Patterns (million), 2010–2017 58

Table 23: Opioids Market, Global, Neuropathic Pain Market Geographical Segmentation ($m), 2002–2010 63

Table 24: Opioids Market, Global, Neuropathic Pain Market Geographical Segmentation ($m), 2010–2017 63

Table 25: Opioids Market, Global, Cancer Pain Revenue ($m), 2002–2010 67

Table 26: Opioids Market, Global, Cancer Pain Revenue ($m), 2010–2017 67

Table 27: Opioids Market, Global, Cancer Pain Annual Cost of Therapy ($), 2002–2010 67

Table 28: Opioids Market, Global, Cancer Pain Annual Cost of Therapy ($), 2010–2017 68

Table 29: Opioids Market, Global, Cancer Pain Treatment Usage Patterns (million), 2002–2010 69

Table 30: Opioids Market, Global, Cancer Pain Treatment Usage Patterns (million), 2010–2017 69

Table 31: Opioids Market, Global, Cancer Pain Market Geographical Segmentation ($m), 2002–2010 75

Table 32: Opioids Market, Global, Cancer Pain Market Geographical Segmentation ($m), 2010–2017 75

Table 33: Opioids Market, Osteoarthritis Pain Global Revenue ($bn), 2002–2010 78

Table 34: Opioids Market, Osteoarthritis Pain Global Revenue ($bn), 2010-2017 78

Table 35: Opioids Market, Osteoarthritis Pain Global Annual Cost of Therapy ($), 2002–2010 79

Table 36: Opioids Market, Osteoarthritis Pain Global Annual Cost of Therapy ($), 2010–2017 79

Table 37: Opioids Market, Osteoarthritis Pain Global Treatment Usage Patterns (million), 2002–2010 80

Table 38: Opioids Market, Osteoarthritis Pain Global Treatment Usage Patterns (million), 2010–2017 81

Table 39: Opioids Market, Osteoarthritis Pain Global Market Geographical Segmentation ($m), 2002–2010 86

Table 40: Opioids Market, Osteoarthritis Pain Global Market Geographical Segmentation ($m), 2010–2017 86

Table 41: Opioids Market, Rheumatoid Arthritis Pain Global Revenue ($m), 2002–2010 89

Table 42: Opioids Market, Rheumatoid Arthritis Global Revenue ($m), 2010–2017 89

Table 43: Opioids Market, Rheumatoid Arthritis Pain Global Annual Cost of Therapy ($), 2002–2010 90

Table 44: Opioids Market, Rheumatoid Arthritis Pain Global Annual Cost of Therapy ($), 2010–2017 90

Table 45: Opioids Market, Rheumatoid Arthritis Pain Global Treatment Usage Patterns ('000), 2002–2010 91

Table 46: Opioids Market, Rheumatoid Arthritis Pain Global Treatment Usage Patterns ('000), 2010–2017 92

Table 47: Opioids Market, Rheumatoid Arthritis Pain Global Market Geographical Segmentation ($m), 2002–2010 97

Table 48: Opioids Market, Rheumatoid Arthritis Pain Global Market Geographical Segmentation ($m), 2010–2017 97

Table 49: Opioids Market, Low Back Pain Global Revenue ($m), 2002–2010 99

Table 50: Opioids Market, Low Back Pain Global Revenue ($m), 2010–2017 99

Table 51: Opioids Market, Low Back Pain Global Annual Cost of Therapy ($), 2002–2010 100

Table 52: Opioids Market, Low Back Pain Global Annual Cost of Therapy ($), 2010–2017 100

Table 53: Opioids Market, Low Back Pain Global Treatment Usage Patterns (million), 2002–2017 101

Table 54: Opioids Market, Low Back Pain Global Treatment Usage Patterns (million), 2010–2017 102

Table 55: Opioids Market, Low Back Pain Global Market Geographical Segmentation ($m), 2002–2010 107

Table 56: Opioids Market, Global, Low Back Pain Market Geographical Segmentation ($m), 2010–2017 107

Table 57: Opioids Market, Post Operative Pain Global Revenue ($bn), 2002–2010 110

Table 58: Opioids Market, Global, Post Operative Pain Revenue ($bn), 2010–2017 110

Table 59: Opioids Market, Post Operative Pain Global Annual Cost of Therapy ($), 2002–2010 110

Table 60: Opioids Market, Post Operative Pain Global Annual Cost of Therapy ($), 2010–2017 111

Table 61: Opioids Market, Post Operative Pain Global Treatment Usage Patterns (million), 2002–2010 112

Table 62: Opioids Market, Post Operative Pain Global Treatment Usage Patterns (million), 2010–2017 112

Table 63: Opioids Market, Post Operative Pain Global Market Geographical Segmentation ($m), 2002–2010 118

Table 64: Opioids Market, Global, Post Operative Pain Market Geographical Segmentation ($m), 2010–2017 118

Table 65: Opioids Market, Others Global Revenue ($m), 2002–2010 120

Table 66: Opioids Market, Others Global Revenue ($m), 2010–2017 120

Table 67: Opioids Market, Global, Revenues by Geography ($bn), 2002–2010 122

Table 68: Opioids Market, Global, Revenues by Geography ($bn), 2010–2017 122

Table 69: Opioids Market, The US, Revenues ($bn), 2002–2010 124

Table 70: Opioids Market, The US, Revenues ($bn), 2010–2017 124

Table 71: Opioids Market, The US, Annual Cost of Therapy ($), 2002–2010 125

Table 72: Opioids Market, The US, Annual Cost of Therapy ($), 2010–2017 125

Table 73: Opioids Market, The US, Treatment Usage Pattern (million), 2002–2010 126

Table 74: Opioids Market, The US, Treatment Usage Pattern (million), 2010–2017 127

Table 75: Opioids Market, Top Five Countries in Europe, Revenues ($bn), 2002–2010 132

Table 76: Opioids Market, Top Five Countries in Europe, Revenues ($bn), 2010–2017 132

Table 77: Opioids Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002–2010 133

Table 78: Opioids Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010–2017 133

Table 79: Opioids Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002–2010 134

Table 80: Opioids Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2010–2017 135

Table 81: Opioids Market, Japan, Revenues ($bn), 2002–2010 139

Table 82: Opioids Market, Japan, Revenues ($bn), 2010–2017 139

Table 83: Opioids Market, Japan Annual Cost of Therapy, ($), 2002–2010 140

Table 84: Opioids Market, Japan Annual Cost of Therapy, ($), 2010–2017 140

Table 85: Opioids Market, Japan, Treatment Usage Pattern (million), 2002–2010 141

Table 86: Opioids Market, Japan, Treatment Usage Pattern (million), 2010–2017 142

Table 87: Opioids Market, Global Major M&A Deals, 2009-2011 163

Table 88: Opioids Market, Global Major Co-developments Deals , 2009-2010 171

1.2 List of Figures

Figure 1: Opioids – A Classification 14

Figure 2: Opioids – Adverse Effects 16

Figure 3: Risk Evaluation and Mitigation Strategy, Components of REMS 17

Figure 4: Risk Evaluation and Mitigation Strategy, Implications for Patients 18

Figure 5: Risk Evaluation and Mitigation Strategy, Number of ED Visits Due To Drug Abuse in the US, 2004 and 2008 20

Figure 6: Opioids Market, Global, Revenue ($bn), 2002–2017 20

Figure 7: Global Revenue of Top Selling Opioids,($'000), 2007–2009 31

Figure 8: Opioids Market, Global, Annual Cost of Therapy ($), 2002–2017 33

Figure 9: Opioids Market, Global Therapeutic Usage Patterns, 2002–2017 34

Figure 10: Opioids Market, Global Diseased Population (million), 2002–2017 36

Figure 11: Opioids Market, Global Treatment Seeking Population (million), 2002–2017 37

Figure 12: Opioids Market, Global Diagnosed Population (million), 2002–2017 38

Figure 13: Opioids Market, Global Prescription Population (million), 2002–2017 39

Figure 14: Opioids Market, Drivers and Restraints, 2010 40

Figure 15: Opioids Market, Fibromyalgia, Global Revenue ($m), 2002–2017 42

Figure 16: Opioids Market, Fibromyalgia Global Annual Cost of Therapy ($), 2002–2017 44

Figure 17: Opioids Market, Fibromyalgia Global Treatment Usage Pattern (million), 2002–2017 45

Figure 18: Opioids Market, Fibromyalgia Global Diseased Population (million), 2002–2017 46

Figure 19: Opioids Market, Fibromyalgia Global Treatment Seeking Population (million), 2002–2017 47

Figure 20: Opioids Market, Fibromyalgia Global Diagnosis Population (million), 2002–2017 48

Figure 21: Opioids Market, Fibromyalgia Global Prescription Population (million), 2002–2017 49

Figure 22: Opioids Market, Fibromyalgia Global Market Segmentation by Geography (%), 2010 and 2017 50

Figure 23: Opioids Market, Fibromyalgia Global Market Geographical Segmentation ($m), 2002–2017 51

Figure 24: Opioids Market, Fibromyalgia Drivers and Restraints, 2010 53

Figure 25: Opioids Market, Global, Neuropathic Pain Revenue ($m), 2002–2017 54

Figure 26: Opioids Market, Global, Neuropathic Pain Annual Cost of Therapy ($), 2002–2017 55

Figure 27: Opioids Market, Global, Neuropathic Pain Treatment Usage Patterns (million), 2002–2017 57

Figure 28: Opioids Market, Global, Neuropathic Pain Diseased Population (million), 2002–2017 58

Figure 29: Opioids Market, Global, Neuropathic Pain Treatment Seeking Population (million), 2002–2017 59

Figure 30: Opioids Market, Global, Neuropathic Pain Diagnosis Population (million), 2002–2017 60

Figure 31: Opioids Market, Global, Neuropathic Pain Prescription Population (million), 2002–2017 61

Figure 32: Opioids Market, Global, Neuropathic Pain Market Segmentation by Geography, 2010 and 2017 62

Figure 33: Opioids Market, Global, Neuropathic Pain Market Geographical Segmentation ($m), 2002–2017 63

Figure 34: Opioids Market, Neuropathic Pain Global Drivers and Restraints, 2010 65

Figure 35: Opioids Market, Global, Cancer Pain Revenue ($bn), 2002–2017 66

Figure 36: Opioids Market, Global, Cancer Pain Annual Cost of Therapy ($), 2002–2017 67

Figure 37: Opioids Market, Global, Cancer Pain Treatment Usage Patterns (million), 2002–2017 68

Figure 38: Opioids Market, Global, Cancer Pain Diseased Population (million), 2002–2017 70

Figure 39: Opioids Market, Global, Cancer Pain Treatment Seeking Population (million), 2002–2017 71

Figure 40: Opioids Market, Global, Cancer Pain Diagnosis Population (million), 2002–2017 72

Figure 41: Opioids Market, Global, Cancer Pain Opioid Prescription Population (million), 2002–2017 73

Figure 42: Opioids Market, Global, Cancer Pain Market Segmentation by Geography, 2010 and 2017 74

Figure 43: Opioids Market, Global, Cancer Pain Market Geographical Segmentation ($m), 2002–2017 75

Figure 44: Opioids Market, Cancer Pain Drivers and Restraints, 2010 76

Figure 45: Opioids Market, Osteoarthritis Pain Global Revenue ($bn), 2002–2017 78

Figure 46: Opioids Market, Osteoarthritis Pain Global Annual Cost of Therapy ($), 2002–2017 79

Figure 47: Opioids Market, Osteoarthritis Pain Global Treatment Usage Patterns (million), 2002–2017 80

Figure 48: Opioids Market, Osteoarthritis Pain Global Diseased Population (million), 2002–2017 81

Figure 49: Opioids Market, Osteoarthritis Pain Global Treatment Seeking Population (million), 2002–2017 82

Figure 50: Opioids Market, Osteoarthritis Pain Global Diagnosis Population (million), 2002–2017 83

Figure 51: Opioids Market, Osteoarthritis Pain Global Prescription Population (million), 2002–2017 84

Figure 52: Opioids Market, Osteoarthritis Pain Global Market Segmentation by Geography (%), 2010 and 2017 85

Figure 53: Opioids Market, Osteoarthritis Pain Global Market Segmentation by Geography (%), 2010 and 2017 86

Figure 54: Opioids Market, Osteoarthritis Pain Drivers and Restraints, 2010 87

Figure 55: Opioids Market, Rheumatoid Arthritis Pain Global Revenue ($m), 2002–2017 88

Figure 56: Opioids Market, Rheumatoid Arthritis Pain Global Annual Cost of Therapy ($), 2002–2017 89

Figure 57: Opioids Market, Rheumatoid Arthritis Pain Global Treatment Usage Patterns (million), 2002–2017 91

Figure 58: Opioids Market, Rheumatoid Arthritis Pain Global Diseased Population (million), 2002–2017 92

Figure 59: Opioids Market, Rheumatoid Arthritis Pain Global Treatment Seeking Population (million), 2002–2017 93

Figure 60: Opioids Market, Rheumatoid Arthritis Pain Global Diagnosis Population (million), 2002–2017 94

Figure 61: Opioids Market, Rheumatoid Arthritis Pain Global Prescription Population (million), 2002–2017 95

Figure 62: Opioids Market, Rheumatoid Arthritis Pain Global Market Segmentation by Geography (%), 2010 and 2017 96

Figure 63: Opioids Market, Rheumatoid Arthritis Pain Global Market Geographical Segmentation ($m), 2002–2017 97

Figure 64: Opioids Market, Rheumatoid Arthritis Pain Drivers and Restraints, 2010 98

Figure 65: Opioids Market, Low Back Pain Global Revenue ($m), 2002–2017 99

Figure 66: Opioids Market, Low Back Pain Global Annual Cost of Therapy ($), 2002–2017 100

Figure 67: Opioids Market, Low Back Pain Global Treatment Usage Patterns (million), 2002–2017 101

Figure 68: Opioids Market, Low Back Pain Global Diseased Population (million), 2002–2017 102

Figure 69: Opioids Market, Low Back Pain Global Treatment Seeking Population (million), 2002–2017 103

Figure 70: Opioids Market, Low Back Pain Global Diagnosis Population (million), 2002–2017 104

Figure 71: Opioids Market, Low Back Pain Global Prescription Population (million), 2002–2017 105

Figure 72: Opioids Market, Low Back Pain Global Market Segmentation by Geography (%), 2010 and 2017 106

Figure 73: Opioids Market, Low Back Pain Global Market Geographical Segmentation ($m), 2002–2017 107

Figure 74: Opioids Market, Low Back Pain Drivers and Restraints, 2010 108

Figure 75: Opioids Market, Global, Post Operative Pain Revenue ($bn), 2002–2017 109

Figure 76: Opioids Market, Post Operative Pain Global Annual Cost of Therapy ($), 2002–2017 110

Figure 77: Opioids Market, Post Operative Pain Global Treatment Usage Patterns (million), 2002–2017 111

Figure 78: Opioids Market, Post Operative Pain Global Diseased Population (million), 2002–2017 113

Figure 79: Opioids Market, Post Operative Pain Global Treatment Seeking Population (million), 2002–2017 114

Figure 80: Opioids Market, Post Operative Pain Global Diagnosis Population (million), 2002–2017 115

Figure 81: Opioids Market, Post Operative Pain Global Prescription Population (million), 2002–2017 116

Figure 82: Opioids Market, Post Operative Pain Global Market Segmentation by Geography (%), 2010 and 2017 117

Figure 83: Opioids Market, Post Operative Pain Global Market Geographical Segmentation ($m), 2002–2017 118

Figure 84: Opioids Market, Post Operative Pain Drivers and Restraints, 2010 119

Figure 85: Opioids Market, Others Global Revenue ($m), 2002–2017 120

Figure 86: Opioids Market, Global, Market Share by Geography (%), 2010 and 2017 121

Figure 87: Opioids Market, Global, Revenues by Geography ($bn), 2002–2017 122

Figure 88: Opioids Market, Top Five Countries in Europe, Revenues ($), 2002–2017 123

Figure 89: Opioids Market, The US, Annual Cost of Therapy ($), 2002–2017 125

Figure 90: Opioids Market, The US, Treatment Usage Pattern (million), 2002–2017 126

Figure 91: Opioids Market, The US, Diseased Population (million), 2002–2017 128

Figure 92: Opioids Market, The US, Treatment Seeking Population (million), 2002–2017 129

Figure 93: Opioids Market, The US, Diagnosed Population (million), 2002–2017 130

Figure 94: Opioids Market, The US, Prescription Population (million), 2002–2017 131

Figure 95: Opioids Market, Top Five Countries in Europe, Revenues ($), 2002–2017 132

Figure 96: Opioids Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002–2017 133

Figure 97: Opioids Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002–2017 134

Figure 98: Opioids Market, Top Five Countries in Europe, Diseased Population (million), 2002–2017 135

Figure 99: Opioids Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2002–2017 136

Figure 100: Opioids Market, Top Five Countries in Europe, Diagnosed Population (million), 2002–2017 137

Figure 101: Opioids Market, Top Five Countries in Europe, Prescription Population (million), 2002–2017 138

Figure 102: Opioids Market, Japan, Revenues ($), 2002–2017 139

Figure 103: Opioids Market, Japan, Annual Cost of Therapy ($), 2002–2017 140

Figure 104: Opioids Market, Japan, Treatment Usage Pattern (million), 2002–2017 141

Figure 105: Opioids Market, Japan, Diseased Population (million), 2002–2017 142

Figure 106: Opioids Market, Japan, Treatment Seeking Population (million), 2002–2017 143

Figure 107: Opioids Market, Japan, Diagnosis Population (million), 2002–2017 144

Figure 108: Opioids Market, Japan, Prescription Population (million), 2002–2017 145

Figure 109: Opioids Market, Global, R&D Pipeline by Indication (%), March 2010 146

Figure 110: Opioids Market, Global, R&D Pipeline by Phase (%), March 2010 147

Figure 111: Opioids Market, Global, Neuropathic Pain R&D Pipeline by Phase (%), 2010 148

Figure 112: Opioids Market, Global, Cancer Pain R&D Pipeline by Phase (%), 2010 149

Figure 113: Opioids Market, Global, SWOT – King Pharmaceuticals, 2010 152

Figure 114: Opioids Market, Global, SWOT – Johnson & Johnson, 2010 154

Figure 115: Opioids Market, Global, SWOT – Orexo, 2010 155

Figure 116: Opioids Market, Global, SWOT – Endo Pharmaceuticals, 2010 156

Figure 117: Opioids Market, Global, SWOT – Cephalon, 2010 157

Figure 118: Opioids Market, Global, SWOT – Purdue Pharma, 2010 158

Figure 119: Opioids Market, Global, SWOT – Mundipharma, 2010 159

Figure 120: Opioids Market, Global, M&A Deals by Indication (%), 2005-2010 160

Figure 121: Opioids Market, Global, M&A Deals by Geography (%), 2005-2010 161

Figure 122: Opioids Market, Global, M&A Deals by Value (%), 2005-2010 162

Figure 123: Opioids Market, Global, Major Licensing Agreements by Indication (%), 2009–2010 165

Figure 124: Opioids Market, Global, Major Licensing Agreements by Geography (%), 2009–2010 166

Figure 125: Opioids Market, Global, Major Licensing Agreements by Phase (%), 2009–2010 167

Figure 126: Opioids Market, Global, Major Licensing Agreements by Value (%), 2009–2010 168

Figure 127: Opioids Market, Global, Major Licensing Agreements by Type (%), 2009–2010 169

Figure 128: Opioids Market, Global, Co-Development Deals By Indication (%), 2009–2010 170

Figure 129: Opioids Market, Global, Co-Development Deals By Geography (%), 2009–2010 170

Figure 130: GBI Research Market Forecasting Model 175

Companies Mentioned

King Pharmaceuticals

Johnson & Johnson

Orexo AB

Endo Pharmaceuticals

Cephalon, Inc.

Purdue Pharma

Mundipharma

To order this report:

Drug and Medication Industry: Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Maharashtra, February 12, 2016 ... Market research report titled Chronic Inflammation Global Clinical ... a snapshot of the global clinical trials landscape ... clinical trials by Region, Country (G7 & E7), ... point status and reviews top companies involved and ...
(Date:2/11/2016)... Feb. 11, 2016 Stem cells are primitive ... by self-renewal and the capacity to differentiate into mature ... discovery, as the first mouse embryonic stem cells were ... until 1995 that the first culturing of embryonic stem ... were not produced until 2006 As a result of ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... ... Society (INS) states that vein visualization technology should be used to ensure patient ... around the world, the INS Standards mandate the use of vein visualization technology ...
(Date:2/13/2016)... ... 13, 2016 , ... When an Au Pair comes all the way around the ... in for and they are often worried things won’t go well. More often than not, ... year’s Au Pair of the Year winner’s all commented how their Au Pairs have become ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi ... Management Solution Providers list for its expertise in eClinical Solutions. DDi has built ... serve the technology needs of global clients. DDi provides smarter technology for Clinical ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Mystic Buddha Publishing ... in Blue SKies Buddha, the biography of Rama - Dr. Frederick Lenz. ... story, the love of a Buddhist teacher for teaching and helping others. Valentine’s ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to introduce ... from U.S. universities who will draw from Siemens’ deep knowledge of product ...
Breaking Medicine News(10 mins):